RxDoctor Payments Data

Ruiqing Sun, MD

Neurology · League City, TXNPI 1841550092

Payments from drug & device makers

$1,526in general payments, 2019–2025

Across 28 payments — averaging $54.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • DIXI Medical USA Corp$824
  • SK Life Science, Inc.$257
  • AbbVie$148
  • Aucta Pharmaceuticals, Inc.$71
  • Acadia Pharmaceuticals Inc$50
  • Jazz Pharmaceuticals Inc.$46
  • plus $131 from 5 others

What the payments were for

  • Food & beverage$1,526100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
DIXI Medical USA Corp1$824
SK Life Science, Inc.2$257
AbbVie7$148
Aucta Pharmaceuticals, Inc.9$71
Acadia Pharmaceuticals Inc1$50
Jazz Pharmaceuticals Inc.1$46
Amgen3$41
CSL Behring1$32
Biogen1$25
Genentech USA, Inc.1$22
Pfizer1$12

How this compares

$1,526 in reported general payments places this provider in the 40th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$32,508
Medicare patients
170
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant13$20,455
Levetiracetam204$5,536
Lacosamide58$5,491
Oxcarbazepine15$1,415
Gabapentin89$1,150
Amitriptyline Hcl92$989
Divalproex Sodium ErDivalproex Sodium21$776
Levetiracetam ErLevetiracetam19$588
RizatriptanRizatriptan Benzoate25$444
Divalproex Sodium19$441
Propranolol Hcl25$402
Lamotrigine44$386
Zonisamide20$335
Pregabalin18$323
Topiramate50$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$148$20,45513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,246 neurology providers in Texas.

Other neurology in League City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →